相关实验视频
Updated: May 6, 2026

07:15
Intranasal Administration of CNS Therapeutics to Awake Mice
Published on: April 8, 2013
59.8K
通过鼻内胰岛素的使用增加了脑中的谷氨酸水平
Taisuke Kawashima1, Wattanaporn Bhadhprasit1, Nobuko Matsumura1
1Department of Pharmacology, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi, Tokyo 173-8605, Japan.
Current issues in molecular biology
|July 23, 2025
概括
鼻内胰岛素通过上调EAAC1和降低AMPK激活来提高大脑谷氨酸 (GSH) 水平. 这表明鼻内胰岛素可能会防止神经退行.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 氧化压力有助于神经退行.
- 胰岛素在大脑抗氧化防御中的作用尚未完全理解.
- 谷氨 (GSH) 是大脑中一种关键的内源性抗氧化剂.
研究的目的:
- 为了研究鼻内胰岛素对大脑GSH水平的影响.
- 阐明胰岛素增强大脑抗氧化防御的机制.
主要方法:
- C57BL/6J小鼠每天接受鼻内胰岛素 (2IU/天) 或盐水7天.
- 测量了大脑和肝脏的GSH水平,血糖和食物摄入量.
- 在小鼠大脑中评估EAAC1,GTRAP3-18和激活AMPK的蛋白质水平.
主要成果:
- 鼻内胰岛素显著增加了海马和中脑GSH水平.
- 胰岛素治疗提高了小鼠大脑中的EAAC1表达.
- 观察到EAAC1和GTRAP3-18之间的相互作用减少,以及激活AMPK水平降低.
结论:
- 鼻腔内注射胰岛素可以提高大脑的GSH水平.
- 该机制涉及EAAC1上调和减少AMPK激活.
- 鼻内胰岛素显示有望增强大脑抗氧化防御神经退行.
相关概念视频
Hormones Regulating Blood Glucose
7.6K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
7.6K
Regulation of Food Intake
2.8K
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
2.8K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.8K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.8K
Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Hypoglycemia and Glucagon
1.3K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K

